Monoclonal Antibody Therapies against Anthrax
AbstractAnthrax is a highly lethal infectious disease caused by the spore-forming bacterium Bacillus anthracis. It not only causes natural infection in humans but also poses a great threat as an emerging bioterror agent. The lethality of anthrax is primarily attributed to the two major virulence factors: toxins and capsule. An extensive effort has been made to generate therapeutically useful monoclonal antibodies to each of the virulence components: protective antigen (PA), lethal factor (LF) and edema factor (EF), and the capsule of B. anthracis. This review summarizes the current status of anti-anthrax mAb development and argues for the potential therapeutic advantage of a cocktail of mAbs that recognize different epitopes or different virulence factors. View Full-Text
Share & Cite This Article
Chen, Z.; Moayeri, M.; Purcell, R. Monoclonal Antibody Therapies against Anthrax. Toxins 2011, 3, 1004-1019.
Chen Z, Moayeri M, Purcell R. Monoclonal Antibody Therapies against Anthrax. Toxins. 2011; 3(8):1004-1019.Chicago/Turabian Style
Chen, Zhaochun; Moayeri, Mahtab; Purcell, Robert. 2011. "Monoclonal Antibody Therapies against Anthrax." Toxins 3, no. 8: 1004-1019.